XTL BIOPHARMACEUTICALS LTD
XTLB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XTLB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XTLB
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing pharmaceutical products for autoimmune diseases and, through its subsidiary Psyga Bio, advancing psychedelic-based therapies for central nervous system disorders.
Key risk: Cash runway risk
Market Cap
$6.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing pharmaceutical products for autoimmune diseases and, through its subsidiary Psyga Bio, advancing psychedelic-based therapies for central nervous system disorders.
- XTL has incurred a net loss of $6,969 thousand for the year ended December 31, 2025, consisting of a loss from continuing operations of $759 thousand and a loss from discontinued operations of $6,210 thousand [sec · filed 2026-06-30].
- As of December 31, 2024, the company had approximately $371 thousand in cash and cash equivalents, compared to $1,401 thousand as of December 31, 2023 [sec · filed 2025-04-30].
- The company's product candidate hCDR1 is planned for advanced clinical studies for systemic lupus erythematosus (SLE) [sec · filed 2024-04-30].
- In June 2026, XTL closed the acquisition of Psyga Bio, which has approved Phase 2a clinical trials expected to commence patient enrollment in the near future across multiple CNS indications [sec · filed 2026-06-30].
- XTL has had no drug product sales to date and has incurred negative cash flow from operations each year since inception [sec · filed 2024-04-30].
What works
- XTL has a diversified pipeline through its subsidiary Psyga Bio, which has approved Phase 2a clinical trials across multiple CNS indications, several of which are fully funded and conducted with leading academic institutions [sec · filed 2026-06-30].
- The company has raised substantial capital historically, with net proceeds of approximately $87.4 million from various private placements, public offerings, and warrant exercises as of December 31, 2024 [sec · filed 2025-04-30].
- XTL is actively expanding its IP portfolio surrounding hCDR1 and seeking new opportunities to acquire additional assets [sec · filed 2024-04-30].
What to weigh
- XTL has a very low cash position of $371 thousand as of December 31, 2024, and an accumulated deficit of approximately $158,246 thousand as of December 31, 2023 [sec · filed 2025-04-30][sec · filed 2024-04-30].
- The company has had no drug product sales to date and expects to continue incurring losses and negative cash flows for the foreseeable future [sec · filed 2024-04-30].
- XTL depends on outside financing to continue activities, and failure to raise additional capital could force it to delay or terminate product development [sec · filed 2024-04-30].
- The company's drug candidates are in clinical stages and require positive clinical results to proceed to later-stage testing or marketing approval, with no guarantee of success [sec · filed 2024-04-30].
From the filings
Quoted directly from source documents.
XTL's net loss for 2025 was $6,969 thousand.
“The Company has incurred a net loss of $6,969 thousands for the year ended December 31, 2025”
SEC filings · June 30, 2026
Cash and cash equivalents as of December 31, 2024 were $371 thousand.
“As of December 31, 2024, we had approximately $371 thousand in cash and cash equivalents”
SEC filings · April 30, 2025
Psyga Bio has approved Phase 2a clinical trials expected to commence patient enrollment soon.
“approved Phase 2a human clinical trials, which are expected to commence patient enrollment in the near future, across multiple indications”
SEC filings · June 30, 2026
XTL has had no drug product sales to date.
“We have had no drug product sales to date.”
SEC filings · April 30, 2024
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of $371k as of Dec 2024 is very low; company depends on outside financing to continue operations [sec · filed 2025-04-30].
- No product revenue — XTL has never generated product sales and expects continued losses and negative cash flows [sec · filed 2024-04-30].
- Clinical development risk — Drug candidates are in clinical stages; positive results are required for advancement and are uncertain [sec · filed 2024-04-30].
- Dilution risk — Future capital raises through securities issuances may dilute existing shareholders [sec · filed 2024-04-30].
What to watch
- Patient enrollment and initial data from Psyga Bio's Phase 2a clinical trials across CNS indications [sec · filed 2026-06-30].
- XTL's ability to secure additional financing or a strategic partner to fund hCDR1 development and operations [sec · filed 2024-04-30].
- Progress of hCDR1 advanced clinical study for SLE [sec · filed 2024-04-30].
- Any new asset acquisitions or in-licensing opportunities as part of XTL's business development strategy [sec · filed 2024-04-30].
Sources: SEC filings · Generated August 10, 2026 · How we verify sources →
Run XTL BIOPHARMACEUTICALS LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XTL BIOPHARMACEUTICALS LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$55K
| Holder | Shares | Value |
|---|---|---|
| smartharvest portfolios, llc | 13,351 | $32K |
| rhumbline advisers | 5,987 | $14K |
| gamma investing llc | 3,388 | $8K |
| noked israel ltd | 49,722 | $120 |
| morgan stanley | 10 | $24 |
Short Interest
as of May 22, 2026- % of float
- 277.5%
- Days to cover
- 0.1
- Shares short
- 680,467
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XTLB short interestFrequently asked questions
What is the AI investment thesis for XTL BIOPHARMACEUTICALS LTD?
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing pharmaceutical products for autoimmune diseases and, through its subsidiary Psyga Bio, advancing psychedelic-based therapies for central nervous system disorders.
Who is the CEO of XTL BIOPHARMACEUTICALS LTD?
Mr. Noam Band is the chief executive officer of XTL BIOPHARMACEUTICALS LTD (XTLB).
Where is XTL BIOPHARMACEUTICALS LTD headquartered?
XTL BIOPHARMACEUTICALS LTD (XTLB) is headquartered in Herzliya, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.